Transitioning from Oral to Transdermal Rivastigmine

Dose Conversion and Titration

• For patients requiring higher doses, the 13.3 mg/24-hour patch is available for all stages of Alzheimer's disease, and dose escalation can be considered if cognitive or functional decline continues despite adequate trial of 9.5 mg/24-hour patch, according to the American Academy of Sleep Medicine 1

Treatment Duration and Assessment

• Allow at least 6-12 months to assess treatment response after the transition, as recommended by medical guidelines 2